This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions (EAGLE)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
dr. W.B. Nagengast, MD, University Medical Center Groningen Identifier:
First received: June 29, 2017
Last updated: NA
Last verified: June 2017
History: No changes posted

To improve detection of esophageal (pre)malignant lesions during surveillance endoscopy of patients at risk of developing malignancies, for example in Barrett's Esophagus (BE), there is a need for better endoscopic visualization and the ability for targeted biopsies. Optical molecular imaging of neoplasia associated biomarkers could form a promising technique to accommodate this need. It is known that the biomarker c-Met is overexpressed in dysplastic and neoplastic areas in BE segments versus normal tissue and has proven to be a valid target for molecular imaging.

Edinburgh Molecular Imaging Ltd (EMI) has developed a fluorescent tracer specifically targeting c-Met by labeling a small peptide to a fluorescent fluorophore: 'EMI-137'. The investigators hypothesize that when EMI-137 is administered intravenously, it accumulates in c-Met expressing high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC), enabling (early) cancer visualization using a newly developed fluorescent fiber-bundle. This hypothesis will be tested in the current pilot intervention study.

Condition Intervention Phase
Barrett Esophagus Esophageal Cancer Dysplasia in Barrett Esophagus Drug: IV-administation of EMI-137 Device: Molecular Fluorescence Endoscopy platform Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Molecular Fluorescence Endoscopy for the Detection of (Pre)Malignant Lesions in Barrett's Esophagus Using a Fluorescent Tracer 'EMI-137' Targeting c-Met: a Single-center Feasibility and Safety Study

Resource links provided by NLM:

Further study details as provided by dr. W.B. Nagengast, MD, University Medical Center Groningen:

Primary Outcome Measures:
  • Tumor-to-background ratio that allows the in vivo detection of (pre)malignant lesions in patients with Barrett's Esophagus using molecular fluorescence endoscopy. [ Time Frame: Day 1 ]
    Calculation of the in vivo tumor-to-background ratio (> 1.5) based on fluorescence intensities in (pre)malignant lesions compared to surrounding healthy esophageal tissue.

  • Safety: the number of participants with symptoms or changes in vital signs (blood pressure, heart frequency and temperature) and/or (serious) adverse events that are related to administration of EMI-137. [ Time Frame: Up to day 3 ]

Secondary Outcome Measures:
  • The correlation of fluorescence signals to histopathology from (pre)malignant lesions and surrounding normal esophageal tissue. [ Time Frame: Up to 1 year ]
  • Identification of fluorescence lesions and correlation with histopathology on subsequent biopsies in the resection surface after endoscopic mucosal resection. [ Time Frame: Up to 1 year ]
  • Quantification of fluorescence signals in vivo and ex vivo of (pre)malignant lesions and normal esophageal tissue using multi-diameter single-fiber reflectance single-fiber fluorescence (MDSFR-SFF) spectroscopy. [ Time Frame: Up to 1 year ]
  • Visualization of the localization and distribution patterns of EMI-137 in the esophagus using ex vivo fluorescence microscopy. [ Time Frame: Up to 1 year ]

Estimated Enrollment: 25
Actual Study Start Date: February 1, 2017
Estimated Study Completion Date: December 1, 2018
Estimated Primary Completion Date: December 1, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IV-tracer EMI-137
  • IV-administration of EMI-137: all patients will receive 0.13 mg/kg of the fluorescent tracer EMI-137 intravenously.
  • Molecular Fluorescence Endoscopy: approximately 2,5 hours after tracer administration, Molecular Fluorescence Endoscopy will be performed with additional measurements of fluorescence signals.
Drug: IV-administation of EMI-137
Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
Other Name: Tracer administation
Device: Molecular Fluorescence Endoscopy platform
A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
Other Name: Fluorescence Endoscopy

Detailed Description:
See brief summary.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years, eligible for a diagnostic and/or therapeutic endoscopy;
  • At least a suspicion of low grade dysplasia (LGD) based on a prior endoscopy;
  • World Health Organization (WHO) performance score of 0-2;
  • Written informed consent;
  • Mentally competent person that is able and willing to comply with study procedures;
  • For female subjects who are of childbearing potential, are premenopausal with intact reproductive organs or are less than 2 years post-menopausal:

    • A negative serum pregnancy test prior to receiving the tracer;
    • Willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter.

Exclusion Criteria:

  • Pregnancy or breast feeding;
  • Advanced stage EAC patient not suitable for endoscopic resection;
  • Medical or psychiatric conditions that compromise the patient's ability to give informed consent;
  • Concurrent anticancer therapy (chemotherapy, radiotherapy, vaccines, immunotherapy) delivered within the last three months prior to the start of the treatment
  • The subject has been included previously in this study or has been injected with another investigational medicinal product within the past six months.
  • History of myocardial infarction (MI), Transient Ischemic Attack (TIA), CerebroVascular Accident (CVA), pulmonary embolism, uncontrolled congestive heart failure (CHF), significant liver disease, unstable angina within 6 months prior to enrollment.
  • The subject had any significant change in their regular prescription or non-prescription medication between 14 days and 1 day prior to Investigational Medicinal Product (IMP) administration. Occasional use of analgesics, such as non-steroid anti-inflammatory drugs and/or paracetamol, was permitted at the discretion of the investigator. Use of hormonal contraceptives is permitted.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03205501

University Medical Center Groningen
Groningen, Netherlands, 9713GZ
Sponsors and Collaborators
University Medical Center Groningen
Principal Investigator: W.B. Nagengast, MD, PhD, PharmD University Medical Center Groningen
Principal Investigator: G.M. van Dam, MD, PhD University Medical Center Groningen
  More Information

Responsible Party: dr. W.B. Nagengast, MD, Principle Investigator, University Medical Center Groningen Identifier: NCT03205501     History of Changes
Other Study ID Numbers: NL59628.042.16
Study First Received: June 29, 2017
Last Updated: June 29, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by dr. W.B. Nagengast, MD, University Medical Center Groningen:

Additional relevant MeSH terms:
Esophageal Neoplasms
Barrett Esophagus
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Abnormalities processed this record on September 21, 2017